Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies
Intelligent Bio Solutions (Nasdaq: INBS) reported its fiscal Q4 and full-year 2025 results, highlighting significant progress in its U.S. market expansion plans and operational performance. The company achieved 16% revenue growth both sequentially and year-over-year in Q4, reaching $843,884, driven by increased drug testing cartridge demand.
Key developments include advancement toward FDA 510(k) clearance for its opiate test system, expansion of its international presence to over 450 accounts across 24 countries, and a 24% year-over-year increase in cartridge sales for Q4. The company implemented operational efficiencies, launched multilingual support, and strengthened its intellectual property with a sixth U.S. patent.
Intelligent Bio Solutions (Nasdaq: INBS) ha presentato i risultati del quarto trimestre e dell鈥檌ntero anno fiscale 2025, sottolineando progressi significativi nell鈥檈spansione sul mercato statunitense e nelle performance operative. Nel Q4 i ricavi sono cresciuti del 16% sia su base sequenziale sia anno su anno, raggiungendo $843.884, trainati da una maggiore domanda di cartucce per test farmacologici.
Tra gli sviluppi principali: avanzamento verso la clearance FDA 510(k) per il sistema di test degli oppiacei, ampliamento della presenza internazionale a oltre 450 account in 24 paesi e un aumento delle vendite di cartucce del 24% anno su anno nel Q4. La societ脿 ha inoltre introdotto efficienze operative, supporto multilingue e rafforzato la propriet脿 intellettuale con un sesto brevetto statunitense.
Intelligent Bio Solutions (Nasdaq: INBS) inform贸 sus resultados del cuarto trimestre y del a帽o fiscal 2025, destacando avances significativos en la expansi贸n de su mercado en EE.听UU. y en su desempe帽o operativo. En el Q4 los ingresos crecieron un 16% tanto secuencialmente como interanual, alcanzando $843,884, impulsados por una mayor demanda de cartuchos para pruebas de drogas.
Entre los hitos: progreso hacia la autorizaci贸n FDA 510(k) para su sistema de detecci贸n de opi谩ceos, ampliaci贸n de su presencia internacional a m谩s de 450 cuentas en 24 pa铆ses y un incremento del 24% interanual en las ventas de cartuchos en el Q4. La compa帽铆a tambi茅n implement贸 eficiencias operativas, lanz贸 soporte multiling眉e y reforz贸 su propiedad intelectual con una sexta patente en EE.听UU.
Intelligent Bio Solutions (Nasdaq: INBS)電� 2025 須岅硠鞐半弰 4攵勱赴 氚� 鞐瓣皠 鞁れ爜鞚� 氚滍憸頃橂┌ 氙戈淡 鞁滌灔 頇曥灔 瓿勴殟瓿� 鞖挫榿 靹标臣鞐愳劀 鞚橂 鞛堧姅 歆勳爠鞚� 氤搓碃頄堨姷雼堧嫟. 4攵勱赴 毵れ稖鞚� 鞝勲秳旮� 氚� 鞝勲厔 雽�牍� 臧侁皝 16% 歃濌皜顷� $843,884毳� 旮半頄堨溂氅�, 鞚措姅 鞎诫 瓴�靷� 旃错姼毽 靾橃殧 歃濌皜臧� 欤茧悳 鞗愳澑鞛呺媹雼�.
欤检殧 雮挫毄鞙茧電� 鞎勴幐瓿� 瓴�靷� 鞁滌姢韰滌潣 FDA 510(k) 鞀轨澑 歆勴枆, 24臧滉淡鞐� 瓯胳硱 450臧� 鞚挫儊 瓿勳爼鞙茧 甑牅鞝� 鞛呾 頇曤寑, 4攵勱赴 旃错姼毽 韺愲Г臧� 鞝勲厔 雽�牍� 24% 歃濌皜頃� 鞝愳澊 韽暔霅╇媹雼�. 霕愴暅 鞖挫榿 須湪靹� 霃勳瀰, 雼り淡鞏� 歆�鞗� 鞁滌瀾, 氙戈淡鞐愳劀 鞐劘 氩堨Ц 韸鬼棃 須嶋摑鞙茧 歆�鞝� 鞛偘甓� 臧曧檾霃� 鞚措（鞏挫鞀惦媹雼�.
Intelligent Bio Solutions (Nasdaq: INBS) a publi茅 ses r茅sultats du quatri猫me trimestre et de l鈥檈xercice 2025, mettant en avant des progr猫s significatifs dans son expansion sur le march茅 am茅ricain et ses performances op茅rationnelles. Au T4, le chiffre d鈥檃ffaires a augment茅 de 16% 脿 la fois s茅quentiellement et en glissement annuel, atteignant 843听884 $, port茅 par une demande accrue de cartouches de d茅pistage de drogues.
Parmi les faits marquants : avanc茅e vers l鈥檋omologation FDA 510(k) pour son syst猫me de d茅tection des opiac茅s, extension de sa pr茅sence internationale 脿 plus de 450 comptes dans 24 pays et hausse de 24% en glissement annuel des ventes de cartouches au T4. L鈥檈ntreprise a en outre mis en 艙uvre des gains d鈥檈fficacit茅 op茅rationnelle, lanc茅 un support multilingue et renforc茅 sa propri茅t茅 intellectuelle avec un sixi猫me brevet am茅ricain.
Intelligent Bio Solutions (Nasdaq: INBS) ver枚ffentlichte die Ergebnisse f眉r das vierte Quartal und das Gesch盲ftsjahr 2025 und hob dabei deutliche Fortschritte bei der Expansion auf dem US-Markt sowie bei der operativen Leistung hervor. Im Q4 stiegen die Ums盲tze sowohl im Quartalsvergleich als auch im Jahresvergleich um 16% auf $843.884, angetrieben durch eine h枚here Nachfrage nach Drogen-Testkassetten.
Wesentliche Entwicklungen umfassen den Fortschritt in Richtung FDA-510(k)-Zulassung f眉r das Opiat-Testsystem, die Ausweitung der internationalen Pr盲senz auf 眉ber 450 Konten in 24 L盲ndern sowie einen 24%igen Anstieg der Kassettverk盲ufe im Q4 gegen眉ber dem Vorjahr. Das Unternehmen setzte operative Effizienzma脽nahmen um, f眉hrte mehrsprachigen Support ein und st盲rkte sein geistiges Eigentum mit einem sechsten US-Patent.
- Q4 revenue increased 16% both year-over-year and quarter-over-quarter to $843,884
- Cartridge sales grew 24% year-over-year in Q4 and 14% for the full fiscal year
- Reader sales increased 15% quarter-over-quarter
- Added 115 new accounts, expanding customer base to over 450 across 24 countries
- Advanced FDA 510(k) clearance process with new positive performance data
- Secured sixth U.S. patent strengthening intellectual property portfolio
- Still limited to Forensic Use Only settings in U.S. market pending FDA clearance
- Requires additional regulatory approvals for expansion in Canada, Indonesia, and Philippines
Insights
INBS shows 16% revenue growth with improving recurring cartridge sales, but still operating at a loss while pursuing FDA clearance.
INBS reported
The company's customer base expansion to over 450 accounts across 24 countries represents impressive penetration for their drug testing technology. Adding 115 new accounts during the fiscal year establishes a
Notably absent from the release are bottom-line metrics. While the company mentions efforts to reduce net losses, no specific profit/loss figures are provided, suggesting INBS remains unprofitable despite the revenue growth. Cash position details are also missing, which raises questions about runway and potential need for additional financing as they pursue FDA clearance.
The regulatory pathway represents both the greatest opportunity and risk. FDA 510(k) clearance for their opiate test would significantly expand their addressable market beyond current Forensic Use Only settings into the broader U.S. drug screening market. While they've submitted performance data and engaged consultants, the timeline and probability of approval remain uncertain, making this a critical inflection point in their growth strategy.
Company advanced efforts to secure U.S. FDA 510(k) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings
Fourth quarter sequential and year-on-year revenue growth of
NEW YORK, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025.
Fiscal 2025 marked a year of growth for the Company, driven by higher-margin cartridge sales, operational streamlining, and regulatory advancements that support future expansion in the U.S. market, beyond current Forensic Use Only settings. The Company continues to expand its commercial presence internationally, with an active customer base exceeding 450 accounts across 24 countries, and 18 distribution partners.
鈥淔iscal 2025 was a pivotal year for our business as we continued to lay the foundation for global growth,鈥� said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. 鈥淲e delivered sequential growth over fiscal quarters three and two, driven by increased cartridge revenue, improved operational discipline, and growing international momentum. As we enter fiscal 2026, we鈥檙e focused on three strategic priorities: further accelerating growth, advancing operational excellence, and expanding beyond Forensic Use Only settings in the U.S. Our FDA regulatory pathway remains on track, and we are committed to achieving FDA clearance to expand into the U.S., the world鈥檚 largest drug screening market, and deliver our non-invasive solution to more organizations seeking fast, dignified, and reliable testing alternatives.鈥�
Progress Toward FDA Clearance and U.S. Market Expansion
INBS remains focused on securing FDA 510(k) clearance for its opiate test system for codeine in the U.S., enabling broader use beyond current Forensic Use Only settings. In fiscal 2025, the Company advanced its regulatory strategy through increased engagement with regulatory consultants, refined clinical study design, and the generation of new scientific and clinical data to support its submission.
- The Company's submission to the FDA was supported by a comprehensive dataset comprising new positive data that further validates the security and performance of its innovative听fingerprint sweat-based drug screening technology.
- INBS submitted performance data derived from advanced quantification methods, including human eccrine sweat testing. An Ultra-Micro Balance scale confirmed the system鈥檚 capability to detect and analyze the minute sweat volumes present in a single fingerprint.
- The application reflects strategic input from specialized FDA consultants and expert third party partners.
- Regulatory expansion efforts beyond the U.S. continue, with active scoping underway in Canada, Indonesia, and the Philippines.
- U.S. market research efforts have progressed beyond initial scoping, with micro-level analysis underway to assess regulatory barriers, relevant drug testing legislation, population distribution, and regional industry concentrations.
Expansion Across Key Markets
Revenue from鈥痵ales of goods in fiscal Q4 increased by
- 2025 fiscal fourth quarter revenue reached
$843,884 , up16% year-on-year from 2024 fiscal fourth quarter revenue of$727,824 and up16% quarter-on-quarter from 2025 fiscal third quarter revenue of$728,867 , reflecting steady sequential growth. - Revenue from cartridge sales increased
9% quarter-on-quarter,24% year-on-year for the fiscal fourth quarter, and14% year-on-year for the full fiscal year. - Revenue from reader sales increased
15% quarter-on-quarter. - The Company secured 115 new accounts throughout the year, bringing the total active customer base to over 450. The Company expects this accelerated pace of new active account growth to continue into the future.
- New distributor partnerships and deployments in large-scale transport, logistics and construction networks underpinned strategic growth across the UK, Europe, and the Middle East.
Operational Efficiencies and Business Localization Strengthen Fundamentals
The Company implemented targeted measures to improve gross margins and reduce net loss, including product enhancements, manufacturing improvements, systems upgrades and the use of localized strategies and automation.
- The multilingual upgrade of the Intelligent Fingerprinting Drug Screening System was completed, with support for Arabic and Latin American Spanish now available.
- Regionally localized websites were launched in Italian, Spanish and Arabic, supporting international partners and end users in Europe, the Middle East, and Latin America.
- The Company fully optimized its CRM system, HubSpot, enabling region-specific workflows, lead tracking, and automation efforts to improve conversion tracking, marketing effectiveness and customer engagement.
- The Company commenced implementation of a new accounting system that will enhance its internal controls by improving efficiency, accuracy, and reliability in financial reporting and data management. Additionally, it commenced implementing a new accounting system for its subsidiary Intelligent Fingerprinting Limited and plans to complete this by the third fiscal quarter of FY 2025鈥�26.
- The addition of a sixth U.S. patent strengthened the Company鈥檚 intellectual property portfolio and reinforced its long-term defensibility.
鈥淲e鈥檝e achieved an enormous amount over fiscal 2025, delivering quarter-on-quarter growth, with accelerated momentum in the second half,鈥� said Spiro Sakiris, Chief Financial Officer at Intelligent Bio Solutions. 鈥淭his consistent performance reflects the growing traction of our testing solutions in key markets and gives us confidence in our trajectory as we move into fiscal 2026.鈥�
About Intelligent Bio Solutions Inc.听
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company鈥檚 current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit https://ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.鈥檚 ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including 鈥渂elieves,鈥� 鈥渆stimates,鈥� 鈥渁nticipates,鈥� 鈥渆xpects,鈥� 鈥減lans,鈥� 鈥減rojects,鈥� 鈥渋ntends,鈥� 鈥減otential,鈥� 鈥渕ay,鈥� 鈥渃ould,鈥� 鈥渕ight,鈥� 鈥渨ill,鈥� 鈥渟hould,鈥� 鈥渁pproximately鈥� or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions鈥� public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.鈥�
[email protected] 鈥�
尝颈苍办别诲滨苍鈥瘄鈥疶飞颈迟迟别谤鈥�
Investor & Media Contact
Valter Pinto, Managing Director鈥�
KCSA Strategic Communications鈥�
PH: (212) 896-1254鈥�
[email protected]
| Intelligent Bio Solutions Inc. Consolidated Balance Sheets | ||||||||
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||
| 听 | 听 | As of June 30, | 听 | 听 | As of June 30, | 听 | ||
| 听 | 听 | 2025 | 听 | 听 | 2024 | 听 | ||
| ASSETS | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Current assets | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Cash and cash equivalents | 听 | $ | 1,019,909 | 听 | 听 | $ | 6,304,098 | 听 |
| Accounts receivable, net | 听 | 听 | 594,614 | 听 | 听 | 听 | 429,704 | 听 |
| Inventories, net | 听 | 听 | 635,215 | 听 | 听 | 听 | 777,537 | 听 |
| Research and development tax incentive receivable | 听 | 听 | 734,408 | 听 | 听 | 听 | 525,332 | 听 |
| Assets held for sale | 听 | 听 | 327,500 | 听 | 听 | 听 | - | 听 |
| Other current assets | 听 | 听 | 826,976 | 听 | 听 | 听 | 497,572 | 听 |
| Total current assets | 听 | 听 | 4,138,622 | 听 | 听 | 听 | 8,534,243 | 听 |
| Property and equipment, net | 听 | 听 | 251,325 | 听 | 听 | 听 | 565,850 | 听 |
| Operating lease right-of-use assets | 听 | 听 | 69,520 | 听 | 听 | 听 | 306,744 | 听 |
| Intangibles, net | 听 | 听 | 3,790,319 | 听 | 听 | 听 | 4,372,026 | 听 |
| Total assets | 听 | $ | 8,249,786 | 听 | 听 | $ | 13,778,863 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| LIABILITIES AND SHAREHOLDERS鈥� EQUITY | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Current liabilities | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Accounts payable and accrued expenses | 听 | $ | 4,534,246 | 听 | 听 | $ | 1,704,568 | 听 |
| Current portion of operating lease liabilities | 听 | 听 | 84,659 | 听 | 听 | 听 | 274,834 | 听 |
| Deferred grant income | 听 | 听 | - | 听 | 听 | 听 | 2,486,668 | 听 |
| Current employee benefit liabilities | 听 | 听 | 534,990 | 听 | 听 | 听 | 469,381 | 听 |
| Notes payable | 听 | 听 | 197,146 | 听 | 听 | 听 | 515,282 | 听 |
| Total current liabilities | 听 | 听 | 5,351,041 | 听 | 听 | 听 | 5,450,733 | 听 |
| Employee benefit liabilities, less current portion | 听 | 听 | 84,921 | 听 | 听 | 听 | 63,615 | 听 |
| Operating lease liabilities, less current portion | 听 | 听 | - | 听 | 听 | 听 | 81,324 | 听 |
| Total liabilities | 听 | 听 | 5,435,962 | 听 | 听 | 听 | 5,595,672 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Commitments and contingencies (Note 16) | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Shareholders鈥� equity | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Common stock, | 听 | 听 | 73,230 | 听 | 听 | 听 | 34,557 | 听 |
| Treasury stock, at cost, 116 shares as of June 30, 2025 and 2024 | 听 | 听 | (1 | ) | 听 | 听 | (1 | ) |
| Additional paid-in capital | 听 | 听 | 65,783,916 | 听 | 听 | 听 | 60,971,740 | 听 |
| Accumulated deficit | 听 | 听 | (62,533,065 | ) | 听 | 听 | (51,964,332 | ) |
| Accumulated other comprehensive loss | 听 | 听 | (327,944 | ) | 听 | 听 | (712,614 | ) |
| Total consolidated Intelligent Bio Solutions Inc. equity | 听 | 听 | 2,996,136 | 听 | 听 | 听 | 8,329,350 | 听 |
| Non-controlling interest | 听 | 听 | (182,312 | ) | 听 | 听 | (146,159 | ) |
| Total shareholders鈥� equity | 听 | 听 | 2,813,824 | 听 | 听 | 听 | 8,183,191 | 听 |
| TOTAL LIABILITIES AND SHAREHOLDERS鈥� EQUITY | 听 | $ | 8,249,786 | 听 | 听 | $ | 13,778,863 | 听 |
| Intelligent Bio Solutions Inc. Consolidated Statements of Operations and Other Comprehensive Income (Loss) | ||||||||
| 听 | ||||||||
| 听 | 听 | Year ended June 30, | 听 | |||||
| 听 | 听 | 2025 | 听 | 听 | 2024 | 听 | ||
| Revenue | 听 | $ | 3,052,532 | 听 | 听 | $ | 3,111,781 | 听 |
| Cost of revenue (exclusive of amortization shown separately below) | 听 | 听 | (1,805,673 | ) | 听 | 听 | (1,686,155 | ) |
| Gross profit | 听 | 听 | 1,246,859 | 听 | 听 | 听 | 1,425,626 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Other income | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Government support income | 听 | 听 | 816,901 | 听 | 听 | 听 | 424,776 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Operating expenses | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Selling, general and administrative expenses | 听 | 听 | (8,883,917 | ) | 听 | 听 | (9,258,496 | ) |
| Development and regulatory approval expenses | 听 | 听 | (2,396,513 | ) | 听 | 听 | (1,673,806 | ) |
| Depreciation and amortization | 听 | 听 | (1,207,875 | ) | 听 | 听 | (1,201,274 | ) |
| Impairment of long-lived assets | 听 | 听 | (220,062 | ) | 听 | 听 | - | 听 |
| Total operating expenses | 听 | 听 | (12,708,367 | ) | 听 | 听 | (12,133,576 | ) |
| Loss from operations | 听 | 听 | (10,644,607 | ) | 听 | 听 | (10,283,174 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Other income (expense), net | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Interest expense | 听 | 听 | (60,890 | ) | 听 | 听 | (167,140 | ) |
| AG真人官方ized foreign exchange loss | 听 | 听 | (911 | ) | 听 | 听 | (1,178 | ) |
| Fair value gain on revaluation of financial instrument | 听 | 听 | - | 听 | 听 | 听 | 175,738 | 听 |
| Interest income | 听 | 听 | 101,522 | 听 | 听 | 听 | 84,822 | 听 |
| Total other income, net | 听 | 听 | 39,721 | 听 | 听 | 听 | 92,242 | 听 |
| Net loss | 听 | 听 | (10,604,886 | ) | 听 | 听 | (10,190,932 | ) |
| Net loss attributable to non-controlling interest | 听 | 听 | (36,153 | ) | 听 | 听 | (34,173 | ) |
| Net loss attributable to Intelligent Bio Solutions Inc. | 听 | $ | (10,568,733 | ) | 听 | $ | (10,156,759 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Other comprehensive income (loss) | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Foreign currency translation gain (loss) | 听 | 听 | 384,670 | 听 | 听 | 听 | (137,118 | ) |
| Total other comprehensive income (loss) | 听 | 听 | 384,670 | 听 | 听 | 听 | (137,118 | ) |
| Comprehensive loss | 听 | 听 | (10,220,216 | ) | 听 | 听 | (10,328,050 | ) |
| Comprehensive loss attributable to non-controlling interest | 听 | 听 | (36,153 | ) | 听 | 听 | (34,173 | ) |
| Comprehensive loss attributable to Intelligent Bio Solutions Inc. | 听 | 听 | (10,184,063 | ) | 听 | 听 | (10,293,877 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 |
| Net loss per share, basic and diluted | 听 | $ | (2.00 | ) | 听 | $ | (6.38 | ) |
| Weighted average shares outstanding, basic and diluted | 听 | 听 | 5,273,643 | 听 | 听 | 听 | 1,592,746 | 听 |
FAQ
What were Intelligent Bio Solutions (INBS) Q4 2025 earnings results?
How many customers does Intelligent Bio Solutions (INBS) have in 2025?
What is the status of INBS FDA clearance process?
How much did INBS cartridge sales grow in Q4 2025?
What operational improvements did INBS implement in 2025?
